REFLAB ApS: Financial statements 2022
CVR: 15322586
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
REFLAB ApS (CVR 15322586) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 3,217,192 and a net result of DKK -646,473 compared with DKK -340,962 the year before. That is a decrease of 6.4% compared with the year before. Equity in the 2022 report amounted to DKK 1,440,429. The solvency ratio was 27.8%. The company had 7 employees in the financial year.
- Gross Profit
- DKK 3,217,192
- Profit/Loss
- DKK -646,473
- Equity
- DKK 1,440,429
- Total Assets
- DKK 5,175,011
- Employees
- 7
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 3.2 mio. | -646 t. | 1.4 mio. | 7 |
| 2021 | - | 3.4 mio. | -341 t. | 2.1 mio. | 7 |
| 2020 | - | 1.9 mio. | -888 t. | 2.4 mio. | 6 |
| 2019 | - | 6.9 mio. | 3.1 mio. | 3.3 mio. | 6 |
| 2018 | - | 3.3 mio. | -426 t. | 242 t. | 8 |
Official annual report
Keep an eye on REFLAB ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
REFLAB ApS has published its annual report for 2021. Gross profit came to DKK 3,435,373, and the net result was DKK -340,962.
About REFLAB ApS
REFLAB ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 1991. The company is registered under the industry Traditionelle, komplementære og alternative behandlingsformer. The company was previously named REFERENCELABORATORIET ApS. The management consists of Gert Pynt Andersen and Katrine Baumann Markussen. The company is owned by R-Biopharm AG. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK 4,582,184 and a net result of DKK -1,792,430 compared with DKK 652,577 the year before. Equity in the 2025 report amounted to DKK -635,048.